Skip to main content

EF Hutton Appoints David Sans as Head of Healthcare

Written by Customer Service on . Posted in Public Companies.

Accomplished healthcare and finance leader brings strategic experience and vision to Healthcare & Life Sciences Investment Banking Team

NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.

David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.  Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib), at ImClone Systems and Head of Corporate Development and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York. Dr. Sans holds a PhD in Chemical Engineering from University Ramon Lull in collaboration with the ETH in Zürich, an MBA in Business Law from Fordham in NYC, and he is the recipient of the Don Sheehan International Scholarship to the Wharton School of Business in Philadelphia. David holds a Fellowship in Anti-Aging and Regenerative Medicine (FAARM) from the American Academy and Board of Regenerative Medicine.

“We continue to see innovation and opportunity across the healthcare continuum in biotechnology, medical devices, healthcare IT, healthcare services, and therapeutics, and are privileged to have someone of David’s caliber serve as Head of Healthcare,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton. “His deep knowledge of the healthcare industry, corporate development experience and wide-ranging relationships are ideal to further expand our coverage in the sector. He will oversee all healthcare transactions at EF Hutton, spearheading and driving a wide range of industry transactions. We believe David and our healthcare team’s insight and reporting provides a critical premium for our clients and investors to keep pace with the change and new discoveries in this rapidly evolving sector, and we look forward to his leadership.”

About EF Hutton

EF Hutton is an investment bank headquartered in New York, NY that provides strategic advice and financing solutions to middle market and emerging growth companies. EF Hutton has a proven track record of providing superior strategic advice to clients across the globe in any sector, with unique access to capital from the USA, Asia, Europe, UAE, and Latin America.

EF Hutton continues to be a leader on Wall Street, having raised over $15.8 billion in capital across more than 265 transactions through a variety of product types. Since 2022, by deal count, EF Hutton has been #1 in US IPO issuance and #1 in SPAC issuance, per Bloomberg and SPAC Insider. Taken together, EF Hutton is one of the most active investment banks in the middle market space. For more information visit efhutton.com.

Contact
Joseph T. Rallo
Chief Executive Officer
590 Madison Avenue, 39th Floor
New York, NY 10022
info@efhutton.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.